< 1 minute read
Sep. 18, 2021

A-1331852: A First-In-Class BCL-XL Inhibitor

A-1331852

first-in-class, bioavailable BCL-XL inhibitor oral efficacy in xenograft, led to ADC dev. from SBDD of prior BH3 mimetics ACS Med. Chem. Lett., Jul. 5, 2020 AbbVie, North Chicago, IL / Genentech

drughunter.com
Drug Hunter Team

A-1331852 is a highly potent, orally bioavailable inhibitor of BCL-XL, blocking a protein-protein interaction resulting in tumor cell apoptosis. The compound was an important tool compound for understanding the biology of BCL-family protein inhibitors (particularly around heme toxicities), and ultimately led to the development of an [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in